Abeona Therapeutics Inc. (NASDAQ: ABEO) stock is down 13% in a month. However, the company recently reported encouraging ABO-102 test results in treating Sanfilippo Syndrome. Sanfilippo mainly affects the CNS causing neurological function deterioration.
MRI data from Phase 1/2 Transfer A study showed that ABO-102 increased corpus callosum, amygdala, and grey matter volumes in three patients with Sanfilippo Syndrome Types A at 24 months relative to patients that didn’t receive the treatment. The company presented the new data at an oral presentation during the 16th International Symposium.
The company’s Research & Clinical Development Head, Vishwas Seshadri, said that brain volume reduction is common in Sanfilippo Syndrome Type A and is related to physical and long-term cognitive disability. Seshadri said the grey matter is vital for cognitive development, amygdala for fear learning and social-emotional development, and corpus callosum for development of motor functions.
The MRI data showed ABO-102’s potential in increasing corpus callosum, amygdala, and grey matter volumes, consistent with past neurocognitive development preservation results. Therefore, ABEO is worth watching in the coming weeks.
On Wednesday, ABEO stock went down 1.60% at $1.24 with more than 487K shares, compared to its average volume of 1.42 million shares. The stock has moved within a range of $1.2200 – 1.2750 after opening the trade at $1.26.